Review of registered clinical trials for the treatment of COVID‐19

Babaei, Fatemeh; Mirzababaei, Mohammadreza; Nassiri‐Asl, Marjan; Hosseinzadeh, Hossein

doi:10.1002/ddr.21762

Cited by 30 publications

(22 citation statements)

References 114 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 13 The duration was proposed based on several registered clinical trials on COVID-19 treatments. 34 The NSO product was previously characterized with 0.7% thymoquinone by high-performance liquid chromatography analysis at the UCL School of Pharmacy, London, UK. 13 It is manufactured by the Good Manufacturing Practice (GMP) certified facility Marnys® (Cartagena, Spain; brand name: CUMINMAR; batch number: E365).…”

Section: Methodsmentioning

confidence: 99%

Nigella sativa for the treatment of COVID-19: An open-label randomized controlled clinical trial

Koshak

Mobeireek

et al. 2021

Complementary Therapies in Medicine

View full text Add to dashboard Cite

Background Effective treatment for Coronavirus Disease-2019 (COVID-19) is under intensive research. Nigella sativa oil (NSO) is a herbal medicine with antiviral and immunomodulatory activities, and has been recommended for the treatment of COVID-19. This study aimed to evaluate the efficacy of NSO treatment in patients with COVID-19. Methods All adult patients with mild COVID-19 symptoms presented to King Abdulaziz University Hospital, Jeddah, Saudi Arabia, were recruited for an open label randomized clinical trial (RCT). They were randomly divided into control or treatment groups, with the latter receiving 500 mg NSO (MARNYS® Cuminmar) twice daily for 10 days. Symptoms were daily monitored via telecommunication. The primary outcome focused on the percentage of patients who recovered (symptom-free for 3 days) within 14-days. The trial was registered at clinicaltrials.gov (NCT04401202). Results A total of 173 patients were enrolled for RCT. The average age was 36(±11) years, and 53% of patients were males. The control and NSO groups included 87 and 86 patients respectively. The percentage of recovered patients in NSO group (54[62%]) was significantly higher than that in the control group (31[36%]; p = 0.001). The mean duration to recovery was also shorter for patients receiving NSO (10.7 ± 3.2 days) compared with the control group (12.3 ± 2.8 days); p = 0.001. Conclusions NSO supplementation was associated with faster recovery of symptoms than usual care alone for patients with mild COVID-19 infection. These potential therapeutic benefits require further exploration with placebo-controlled, double-blinded studies.

show abstract

Section: Methodsmentioning

confidence: 99%

Nigella sativa for the treatment of COVID-19: An open-label randomized controlled clinical trial

Koshak

Mobeireek

et al. 2021

Complementary Therapies in Medicine

View full text Add to dashboard Cite

show abstract

“…Clinical trials of vaccines and therapeutics have been performed at an unprecedented pace 6 , leading to the emergency authorisation of several vaccine candidates for susceptible populations in December 2020 7 . Treatment strategies under investigation include medication with anti-viral, anti-inflammatory and immunomodulatory properties 8 .…”

Section: Introductionmentioning

confidence: 99%

The cellular immune response to COVID-19 deciphered by single cell multi-omics across three UK centres

Stephenson¹,

Reynolds²,

Botting³

et al. 2021

Preprint

View full text Add to dashboard Cite

The COVID-19 pandemic, caused by SARS coronavirus 2 (SARS-CoV-2), has resulted in excess morbidity and mortality as well as economic decline. To characterise the systemic host immune response to SARS-CoV-2, we performed single-cell RNA-sequencing coupled with analysis of cell surface proteins, providing molecular profiling of over 800,000 peripheral blood mononuclear cells from a cohort of 130 patients with COVID-19. Our cohort, from three UK centres, spans the spectrum of clinical presentations and disease severities ranging from asymptomatic to critical. Three control groups were included: healthy volunteers, patients suffering from a non-COVID-19 severe respiratory illness and healthy individuals administered with intravenous lipopolysaccharide to model an acute inflammatory response. Full single cell transcriptomes coupled with quantification of 188 cell surface proteins, and T and B lymphocyte antigen receptor repertoires have provided several insights into COVID-19: 1. a new non-classical monocyte state that sequesters platelets and replenishes the alveolar macrophage pool; 2. platelet activation accompanied by early priming towards megakaryopoiesis in immature haematopoietic stem/progenitor cells and expansion of megakaryocyte-primed progenitors; 3. increased clonally expanded CD8+ effector:effector memory T cells, and proliferating CD4+ and CD8+ T cells in patients with more severe disease; and 4. relative increase of IgA plasmablasts in asymptomatic stages that switches to expansion of IgG plasmablasts and plasma cells, accompanied with higher incidence of BCR sharing, as disease severity increases. All data and analysis results are available for interrogation and data mining through an intuitive web portal. Together, these data detail the cellular processes present in peripheral blood during an acute immune response to COVID-19, and serve as a template for multi-omic single cell data integration across multiple centers to rapidly build powerful resources to help combat diseases such as COVID-19.

show abstract

“…Several antiviral strategies have been proposed and almost all steps of viral replication have been targeted. All registered clinical trials using antiviral strategies against SARS-CoV-2 have been reviewed [ 311 ]. Chemical molecules tested in clinical trials are gathered in Table 1 and the mechanisms of action of these antivirals on viral life cycle are shown in Figure 3 .…”

Section: Therapeutic Management Of Patients With Covid-19mentioning

confidence: 99%

COVID-19 and Dentistry in 72 Questions: An Overview of the Literature

Derruau

Bouchet

Nassif

et al. 2021

JCM

View full text Add to dashboard Cite

The outbreak of Coronavirus Disease 2019 (COVID-19), caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), has significantly affected the dental care sector. Dental professionals are at high risk of being infected, and therefore transmitting SARS-CoV-2, due to the nature of their profession, with close proximity to the patient’s oropharyngeal and nasal regions and the use of aerosol-generating procedures. The aim of this article is to provide an update on different issues regarding SARS-CoV-2 and COVID-19 that may be relevant for dentists. Members of the French National College of Oral Biology Lecturers (“Collège National des EnseignantS en Biologie Orale”; CNESBO-COVID19 Task Force) answered seventy-two questions related to various topics, including epidemiology, virology, immunology, diagnosis and testing, SARS-CoV-2 transmission and oral cavity, COVID-19 clinical presentation, current treatment options, vaccine strategies, as well as infection prevention and control in dental practice. The questions were selected based on their relevance for dental practitioners. Authors independently extracted and gathered scientific data related to COVID-19, SARS-CoV-2 and the specific topics using scientific databases. With this review, the dental practitioners will have a general overview of the COVID-19 pandemic and its impact on their practice.

show abstract

Review of registered clinical trials for the treatment of COVID‐19

Cited by 30 publications

References 114 publications

Nigella sativa for the treatment of COVID-19: An open-label randomized controlled clinical trial

Nigella sativa for the treatment of COVID-19: An open-label randomized controlled clinical trial

The cellular immune response to COVID-19 deciphered by single cell multi-omics across three UK centres

COVID-19 and Dentistry in 72 Questions: An Overview of the Literature

Contact Info

Product

Resources

About